Word

ODYSSION

Status

Registered

Status Code

700

Status Date

Tuesday, February 6, 2024

Serial Number

79352298

Registration Number

7296103

Registration Date

Tuesday, February 6, 2024

Mark Type

4

Filing Date

Tuesday, May 24, 2022

Published for Opposition

Tuesday, November 21, 2023

Trademark Owner History

OMASS Therapeutics Limited - Original Registrant

Classifications

5 Pharmaceutical and veterinary preparations and substances for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; biopharmaceutical preparations and substances for treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; chemical, biochemical and biological preparations for medical and veterinary purposes for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; cells, cell lines, and cell cultures, all being cells for medical use, for use in the production of proteins for therapeutic use; reagents for medical use, namely, proteins being medical therapeutic reagents; therapeutic antibodies; vaccines

1 Reagents for use in medical research and scientific research being biological analysis; proteins for use in the manufacture of pharmaceuticals and reagents; proteins in raw material form for use in medical research; cells, cell lines, and cell cultures, all being cells for clinical laboratory use, for use in the production of proteins for therapeutic use

42 Scientific and technological services, namely, scientific research and design relating thereto in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; laboratory research services in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; medical and pharmacological research services; scientific research, namely, scientific analysis and testing being measurement of substances in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; scientific analysis and measurement of molecules and characteristics in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; bioanalysis services; scientific imaging services; biochemical analysis; scientific research and development services; medical research and medical development services in the field of immunology, genetic conditions, oncology, immuno-oncology, ophthalmology, haematology, neurology, respiratory diseases, metabolic conditions, infectious diseases and cardiovascular diseases; pharmaceutical research and development services; biological research and analysis; biomedical research services; biotechnological research, namely, biotechnology scientific testing, in the biotechnical, biomedical and pharmaceutical fields; chemical research and analysis; research and development of new products for others in the biotechnical, biomedical and pharmaceutical fields; pharmaceutical research and development for the pharmaceutical industry; research and development of vaccines and medicines; scientific research and development services in the field of antibodies; scientific research and development services in the field of antibody technology; scientific research and development services in the field of immunology; medical laboratory services; research of pharmaceuticals; research relating to molecular sciences; research relating to pharmaceuticals; biopharmaceutical research, development and testing being product testing services; drug discovery services; product development, namely, drug development services; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; scientific research and development of molecules for therapeutic purposes; consultancy, advisory and information services in relation to all the aforesaid services

Trademark Events

Oct 13, 2022

Sn Assigned For Sect 66a Appl From Ib

Oct 14, 2022

New Application Office Supplied Data Entered

Oct 18, 2022

Application Filing Receipt Mailed

Mar 13, 2023

Assigned To Examiner

Mar 15, 2023

Non-Final Action Written

Mar 16, 2023

Non-Final Action (Ib Refusal) Prepared For Review

May 4, 2023

Refusal Processed By Mpu

May 4, 2023

Non-Final Action Mailed - Refusal Sent To Ib

May 24, 2023

Refusal Processed By Ib

Jul 19, 2023

Teas Response To Office Action Received

Jul 19, 2023

Correspondence Received In Law Office

Jul 20, 2023

Teas/Email Correspondence Entered

Sep 18, 2023

Assigned To Examiner

Oct 7, 2023

Change Of Name/Address Rec'd From Ib

Oct 16, 2023

Examiners Amendment -Written

Oct 16, 2023

Examiners Amendment E-Mailed

Oct 16, 2023

Notification Of Examiners Amendment E-Mailed

Oct 16, 2023

Examiner's Amendment Entered

Oct 16, 2023

Approved For Pub - Principal Register

Nov 1, 2023

Notification Of Notice Of Publication E-Mailed

Nov 1, 2023

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Nov 21, 2023

Published For Opposition

Nov 21, 2023

Official Gazette Publication Confirmation E-Mailed

Nov 1, 2023

Notification Of Possible Opposition Sent To Ib

Nov 21, 2023

Notification Processed By Ib

Feb 6, 2024

Registered-Principal Register

Feb 6, 2024

Notice Of Registration Confirmation Emailed

May 6, 2024

Final Disposition Notice Created, To Be Sent To Ib

May 10, 2024

Final Disposition Notice Sent To Ib

May 10, 2024

Final Disposition Processed